已发表论文

急性髓性白血病的耐药机制

 

Authors Zhang J, Gu Y, Chen B

Received 20 October 2018

Accepted for publication 18 January 2019

Published 11 March 2019 Volume 2019:12 Pages 1937—1945

DOI https://doi.org/10.2147/OTT.S191621

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Justinn Cochran

Peer reviewer comments 2

Editor who approved publication: Dr Takuya Aoki

Abstract: Acute myeloid leukemia (AML) is a kind of malignant hematopoietic system disease characterized by abnormal proliferation, poor cell differentiation, and infiltration of bone marrow, peripheral blood, or other tissues. To date, the first-line treatment of AML is still based on daunorubicin and cytosine arabinoside or idarubicin and cytosine arabinoside regimen. However, the complete remission rate of AML is still not optimistic, especially in elderly patients, and the recurrence rate after complete remission is still high. The resistance of leukemia cells to chemotherapy drugs becomes the main obstacle in the treatment of AML. At present, the research on the mechanisms of drug resistance in AML is very active. This article will elaborate on the main mechanisms of drug resistance currently being studied, including drug resistance-related proteins and enzymes, gene alterations, micro RNAs, and signal pathways.
Keywords: drug resistance, P-glycoprotein, gene alterations, signaling pathway




Figure 1 Four common publicly recognized mechanisms of drug resistance in AML.